According to FutureWise analysis, the cell cryopreservation market in 2025 is US$13.68 billion, and is expected to reach US$70.35 billion by 2033 at a CAGR of 22.71%. The cell cryopreservation market is experiencing significant growth, primarily driven by the increasing demand for cell-based therapies, stem cell banking, and regenerative medicine. This expansion can be attributed to a rising interest in stem cell therapies and biobanking, complemented by increased investments in research and development. Notable advancements in cryopreservation technologies are also playing a critical role in supporting market growth. As the demand for cell-based therapeutics and personalized medicine continues to rise, substantial opportunities are emerging for stakeholders on a global scale. The biotechnology and pharmaceutical sectors are ramping up research and development activities, further boosting market expansion. Additionally, the growing adoption of biobanking and personalized medicine is intensifying the need for reliable long-term solutions for cell preservation. Cell cryopreservation is the process of cooling and preserving living cells at extremely low temperatures to maintain their viability and functionality for future use. This is accomplished by adding cryoprotective agents to the cells, protecting them from damage during the freezing process, and gradually cooling them to temperatures where metabolic activity ceases. The frozen cells can then be stored for extended periods and thawed for various applications, including research, medical treatments, and biotechnology. This method is especially valuable for preserving rare or hard-to-culture cell types.The market is particularly influenced by the demand for personalized medicine, regenerative therapies, and stem cell research, all of which require high-quality cell samples for future applications. Within the cell cryopreservation market, the biobanking industry emerges as a key segment, driven by the increasing requirement for high-quality cell samples for research and clinical purposes. The pharmaceutical and biotechnology sectors are significant users of cryopreservation services, as they need large volumes of high-quality cell lines for drug discovery and development.Looking ahead, the emphasis on developing innovative cryopreservation techniques, along with the integration of automation and robotics in the process, is expected to further catalyze market growth in the coming years.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Cell Cryopreservation Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=12167&type=requestsample

By Product Type

• Cryoprotectant Agents
• Glycerol
• Dimethyl Sulfoxide (DMSO)
• Others
• Equipment
• Incubators
• Liquid Nitrogen Supply Tanks
• Freezers
• Others

By Application

• Stem Cells
• Oocytes and Embryos
• Sperm, Semen, and Testicular Tissue
• Hepatocytes
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Biobank
• Others
• Wholesale

• • Retail (in-store)
  • Distributors/ Franchises

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Cell Cryopreservation Market:

• General Electric Company
• Thermo Fisher Scientific Inc.
• Merck KGaA
• AMS Biotechnology Limited
• Miltenyi Biotec GmbH
• BioLifeSolutions Inc.
• HiMedia Laboratories Pvt. Ltd.
• PromoCell GmbH
• Corning Incorporated
• Cooper Companies, Inc.
• Planer PLC

Recent developments by key players in the Cell Cryopreservation Market:

BioLifeSolutions Inc.

• In April 2025, BioLife acquired PanTHERA CryoSolutions, which added proprietary Ice Recrystallization Inhibitor (IRI) technology and enhanced its cell preservation offerings.
• As of the first quarter of 2025, BioLife processed 13 new FDA Master File cross-references, integrating their biopreservation media into 17 commercial cell and gene therapies, with further expansion anticipated shortly.

Thermo Fisher Scientific Inc.

• Launched the TSV series of ULT freezers in August 2023 (Made in India), offering enhanced temperature uniformity and stability—ideal for long-term cell storage and viability preservation
• The company is expanding its pharma services footprint in 2025, including building an additional 5,000? L and 2,000? L bioreactors at key sites (St. Louis and Switzerland), enhancing biologics manufacturing capacity relevant for cell-therapy supply chains

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=12167&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Cell Cryopreservation Market By Product Type, By Application, By End User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com